The Sexual Medicine Society of North America (SMSNA) has issued a position statement on the use of “regenerative” therapies for erectile dysfunction, including shock wave, platelet rich plasma, and stem cell treatments.
In a strongly-worded statement, the Society comes out against the commercial offering of these experimental therapies.
While acknowledging that there is scientific evidence supporting the potential of shock wave and stem cell therapies, the Society emphasizes that “there is an absence of robust clinical trial data supporting their efficacy and long-term safety in humans.”
The Society strongly encourages the development of new treatments, supported by clinical research.
The position statement concludes by saying:
“…given the current lack of regulatory agency approval for any restorative (regenerative) therapies for the treatment of ED and until such time as approval is granted, SMSNA believes that the use of shock waves or stem cells or platelet rich plasma is experimental and should be conducted under research protocols in compliance with Institutional Review Board approval. Patients considering such therapies should be fully informed and consented regarding the potential benefits and risks. Finally, the SMSNA advocates that patients involved in these clinical trials should not incur more than basic research costs for their participation.”